Product Description
Enfuvirtide is used along with other medications to treat human immunodeficiency virus (HIV) infection. Enfuvirtide is in a class of medications called HIV entry and fusion inhibitors. It works by decreasing the amount of HIV in the blood. Although enfuvirtide does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. (Sourced from: https://medlineplus.gov/druginfo/meds/a603023.html)
Mechanisms of Action: HIV Fusion Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Italy | Korea | Latvia | Lithuania | Mexico | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Thailand | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|